Suchergebnisse - "Heuck, Christoph"

PubPharm (126)

1

Correction : GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

enthalten in: Blood cancer journal | 2024

von Rodriguez-Otero, P. | van de Donk, N. | Pillarisetti, K. | +13

ErratumFor: Blood Cancer J. 2024 Feb 2;14(1):24. - PMID 38307865

2

GPRC5D as a novel target for the treatment of multiple myeloma : a narrative review

enthalten in: Blood cancer journal | 2024

von Rodriguez-Otero, P. | van de Donk, N. | Pillarisetti, K. | +13

ErratumIn: Blood Cancer J. 2024 Mar 6;14(1):40. - PMID 38448422

3

Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses

enthalten in: Europäisches Patentamt | 2023

von BANDEKAR RAJESH | CLEMENS PAMELA | HEUCK CHRISTOPH | +2

4

Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone

enthalten in: Europäisches Patentamt | 2023

von BANDEKAR RAJESH | CLEMENS PAMELA | HEUCK CHRISTOPH | +2

5

Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone

enthalten in: Europäisches Patentamt | 2023

von BANDEKAR RAJESH | CLEMENS PAMELA | HEUCK CHRISTOPH | +2

6

Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone

enthalten in: Europäisches Patentamt | 2023

von BANDEKAR RAJESH | CLEMENS PAMELA | HEUCK CHRISTOPH | +2

7

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

enthalten in: Haematologica | 2022

von Usmani, S. | Nahi, H. | Legiec, W. | +25

8

Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses

enthalten in: Europäisches Patentamt | 2022

von BANDEKAR RAJESH | CLEMENS PAMELA | HEUCK CHRISTOPH | +2

9

Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

enthalten in: Blood | 2022

von Cavo, M. | San-Miguel, J. | Usmani, S. | +24

CommentIn: Blood. 2022 Feb 10;139(6):799-802. - PMID 35142848

10

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

enthalten in: Blood | 2022

von San-Miguel, J. | Avet-Loiseau, H. | Paiva, B. | +24

CommentIn: Blood. 2022 Jan 27;139(4):469-471. - PMID 35084473

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]